Curated News
By: NewsRamp Editorial Staff
June 04, 2024
Clene Announces Significant Updates to ACT-EAP for CNM-Au8 Compassionate Use in ALS
Discuss on Reddit
Discuss on SubstackTLDR
- Clene's updates to their ACT-EAP program for ALS compassionate use provide a crucial advantage for participants seeking treatment.
- Clene's optimized manufacturing, operational, and personnel processes allow for expanded capacity to accommodate up to 180 participants in the ACT-EAP program.
- Clene's dedication to improving mitochondrial health and protecting neuronal function in neurodegenerative diseases like ALS makes the world a better place by offering hope to patients and their families.
- The collaboration among Clene, Columbia University, and Synapticure in the ACT-EAP program for ALS compassionate use was funded by the ACT for ALS Act, signed into law in December 2021.
Impact - Why it Matters
This news matters because it highlights the efforts of Clene to expand access to treatment programs for ALS, a fatal neurodegenerative disease with no known cure. The collaboration with Columbia University and Synapticure, funded by the ACT for ALS Act, demonstrates the commitment to addressing the crucial need for accessible therapies. The expansion of the program's capacity to accommodate up to 180 participants is a significant step in improving the quality of life for ALS patients.
Summary
Clene, a clinical-stage biopharmaceutical company, has announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8 compassionate use in ALS. The program's capacity has been expanded to accommodate up to 180 participants, addressing the crucial need for accessible treatment programs for ALS, a fatal neurodegenerative disease with no known cure. This collaboration among Clene, Columbia University, and Synapticure was funded by the ACT for ALS Act, signed into law by Congress and President Biden in December 2021.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Announces Significant Updates to ACT-EAP for CNM-Au8 Compassionate Use in ALS
